Dr. Danyi Quan is the Chief Scientific Officer of Xel Pharmaceuticals, Inc. and has more than 20 years of experience in the pharmaceutical industry. Dr. Quan received her Ph.D. in Pharmaceuticals at Hoshi University, Tokyo, Japan, and did her post-doctoral research work at the University of California, San Francisco, School of Medicine, Department of Dermatology, Dr. Howard Maibach’s laboratory.
Dr. Quan is a leading expert in advanced drug delivery systems, including transdermal drug delivery, topical drug delivery, fast-dissolving drug delivery, and controlled-release drug delivery. Also, Dr. Quan is actively involved in research and product development of Traditional Chinese Medicines (TCMs) by combining advanced drug delivery technologies and the TCM Ying-Yang concept to nutraceutical and cosmeceutical products. At Xel, Dr. Quan and her team invented the cold water cell-broken extraction technologies, finer-print chromatogram quality control methods and nano technologies for nutritional ingredients, and developed dozens of innovative nutritional and cosmeceutical products.
Dr. Quan has published over 25 scientific papers in top level pharmaceutical and medical journals, over 25 technical abstracts, and two book chapters. Dr. Quan also holds more than 15 U.S. and international patents. Currently, Dr. Quan is the adjunct professor for University of the Pacific, California; School of Pharmacy, University of North Dakota.
“Our team has worked on the reformulation of MonaVie’s juices in the past year, and I have been impressed with MonaVie’s commitment to strengthen its products and technology. We’ve already made a lot of progress, and I am happy to be a part of the MonaVie Scientific Advisory Board and believe that MonaVie will continue to lead out in the direct selling industry.”
No comments:
Post a Comment